MAIN TEXT
In the last two decades there have been impressive demonstrations of computational protein design to create diverse new protein structures spanning helical (1) (2) (3) (4) (5) , alpha-beta(6-8) and beta- 5 sheet (9, 10) folds. In contrast, progress in our ability to computationally design arbitrary protein function de novo lags far behind, with relatively few examples that often required screening of many design variants followed by subsequent experimental optimization (11, 12) . Moreover, many advanced functions present in nature have not yet been realized by computational protein design. One such unsolved challenge is the de novo design of small molecule sensor/actuators in 10 which ligand binding by a protein directly controls changes in downstream functions, a key aspect of cellular signal transduction (13) .
Fundamentally, sensing and responding to a small molecule signal requires both recognition of the target and linking target recognition to an output response. Exciting recent progress has been 15 made with the design of proteins recognizing new ligands (10, 11, (14) (15) (16) . A general solution to the second problem, coupling ligand recognition to diverse output responses, has remained challenging. Existing approaches have used a ligand that fluoresces upon binding (10) , engineered the sensor components to be unstable and hence inactive in the absence of the ligand (14, 17) , or repurposed an allosteric transcription factor (18) . These strategies constrain the 20 input signals or output responses that can be used, since they require fluorescent ligands, tuning of the energetic balance between ligand binding and protein stabilization, or coupling to a transcriptional output while preserving allosteric mechanisms.
Here we describe a new computational strategy to engineer protein complexes that can sense a small molecule and respond directly using different biological outputs, creating modular sensor/response systems. Distinct from prior work (10, 11, 14, 15) that reengineered existing binding sites or placed ligands into preformed cavities, we build small molecule recognition sites de novo into heterodimeric protein-protein interfaces, to create new and programmable 5 chemically induced dimerization systems (CIDs). This strategy is inspired by naturally occurring and reengineered CID systems (19) that have been widely used but are limited to a small number of existing or similar input molecules. We reasoned that computationally designed synthetic CIDs would similarly link binding of a target small molecule to modular cellular responses through genetically encodable fusions of each sensor half protein to a split reporter (Fig. 1A) , but 10 would respond to new, user-defined inputs.
To demonstrate this strategy, we chose farnesyl pyrophosphate (FPP) as the target ligand. FPP is an attractive target because it is a toxic intermediate in a commonly-engineered terpenoid biosynthesis pathway for the production of valuable terpenoid compounds, including the anti- 15 malarial drug artemisinin (20) . Our computational strategy (Fig. 1B, Supplemental Methods) proceeds in four main steps: (i) defining the geometries of minimal FPP binding sites comprised of 3-4 side chains (termed "motif residues") that form key hydrophobic and hydrogen bonding interactions with the target ligand; (ii) modeling these geometries into a dataset of heterodimeric protein-protein interfaces (termed "scaffolds") and computationally screening for coarsely 20 compatible scaffolds(21); (iii) accommodating the de novo built binding sites in these scaffolds using new flexible backbone design methods not previously tested in forward-engineering applications(22-24) ("reshaping"); and (iv) ranking individual designs for testing according to several design metrics including ligand binding energy predicted using the Rosetta force field (25) and ligand burial.
Starting with 5 FPP binding site geometries and up to 3462 heterodimeric scaffolds, we selected the most highly ranked designs across three engineered scaffolds for a first round of 5 experimental testing (Fig. 1B, Supplemental Methods) : the FKBP/FRB complex originally responsive to rapamycin(26) (1 design), a complex between the bacterial signaling proteins RapF and ComA (27) (4 designs) and a synthetic complex between maltose binding protein (MBP) and an ankyrin repeat (AR) protein(28) (4 designs) ( Fig. 2A, Table S1, Fig. S1 ). While the ligand was placed into the original rapamycin binding site in FKBP/FRB, binding sites in the other two 10 complexes were modeled de novo.
To test these computationally designed FPP sensors, we genetically fused the engineered sensor proteins to a well-studied split reporter, the enzyme murine dihydrofolate reductase (mDHFR (29) , Fig. 2B, Appendix 1) , and expressed the fusion constructs in E. coli. We reasoned 15 that functional sensors should exhibit increased growth due to split mDHFR complementation in the presence of FPP under conditions where the endogenous E. coli DHFR protein was specifically inhibited by trimethoprim. Since FPP does not efficiently enter E. coli, we added its metabolic precursor, mevalonate, to the growth medium and co-expressed an engineered pathway of 5 enzymes (20) (Fig. 2B) to produce FPP from mevalonate in the cells. We then 20 monitored sensor function as change in growth in the presence or absence of mevalonate under otherwise identical conditions (Fig. 2B, Supplemental Methods) . In the following, we denote designs by their scaffold (S1, S2, S3), design generation (1, 2, 3) and consecutive letter (A, B, etc.; for details see Table S1 , Fig. S1 ).
While 7 of the 9 selected designs showed only a small (S2-1A, B, C, D; S3-1A, B) or no signal (S1-1A), two designs (S3-1C, D) displayed a robust signal response to FPP (Fig. 2C, Fig. S2 ). 5 Both designs resulted from the MBP-AR scaffold (S3, Fig. 2A) . For this scaffold, we also generated two libraries: library 1 based on our ensemble design predictions ( Fig. 2A, Table S2 ), and library 2 using error-prone PCR starting from design S3-1C. We screened 3×10
5 members of each library and selected 1536 clones from each library after enrichment for growth via split mDHFR complementation. The selected clones were then subjected to an array-based colony- 
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To further characterize the identified best design, S3-2A (Table S1 ), we performed single site saturation mutagenesis at 11 positions (both previously designed and additional second shell positions). We tested the resulting mutants with the growth-based split mDHFR reporter under more stringent conditions by increasing the trimethoprim concentration (Table S3 , Fig. S6 ).
While the original, computationally chosen amino acid at most positions appeared to be optimal under these conditions, we saw considerable improvements for mutations at two positions, R194A (design S3-2B) and R194A / L85G (design S3-2C, Fig. 2A ). Designs S3-2B and S3-2C 5 displayed increasing responses to the presence of mevalonate at higher trimethoprim concentrations ( Fig. 2D) . For the most active design, S3-2C, we confirmed that the sensor signal was dependent on expression of the sensor proteins ( whether the sensor signal of design S3-2C was dependent on the concentration of FPP, using increasing concentrations of mevalonate added extracellularly as a proxy (Fig. 2G) .
Interestingly, while the sensor signal initially increased with increasing concentrations of mevalonate, as expected, the signal decreased again at the highest mevalonate concentration 20 tested. This behavior is likely due to the toxicity of FPP known to decrease growth at this mevalonate concentration (20) . We confirmed a consistent dependency of the sensor signal on Taken together, these results confirmed that sensor function in E. coli was specific to FPP produced via an engineered pathway, dependent on key residues in the engineered binding site, dose-dependent in E. coli, and sensitive to FPP concentrations in a relevant range (i.e. below the toxicity level). 5 To confirm biochemically that FPP increases the binding affinity of the AR-MBP complex as designed, we purified the designed AR and MBP proteins without attached reporters (Supplemental Methods; these constructs contained several previously published mutations to stabilize AR (30) , which when tested in the split mDHFR reporter assay led to active sensor S3-10 2D, Table S1 , Fig. S8, Appendix 2) . We determined the apparent binding affinity of the designed AR and MBP proteins comprising the S3-2D sensor (Fig. 3A, Table S1 , Fig. S1 ) in the absence and presence of 200 µM FPP using biolayer interferometry with streptavidin-biotin coupling (Fig. 3B, Fig. S9 , Supplemental Methods). The presence of FPP led to a greater than 100-fold stabilization of the interaction between the AR and MBP proteins comprising sensor 15 S3-2D (from >200 µM to 2.1 µM, Fig. 3C ). Binding of FPP to the designed AR component of S3-2D alone was weak and binding of FPP to the designed MBP component of S3-2D alone not detectable (Fig. 3D) . Taken together, these results confirm in vitro with purified components that design S3-2D functions as a CID system responding to FPP. 20 To determine whether FPP is recognized in the de novo engineered binding site as predicted by the design model, we determined a 2.2 Å resolution crystal structure of the ternary complex of FPP bound in the engineered AR-MBP interface (Supplemental Methods; Table S4 ). The crystal structure of the bound complex is in excellent overall agreement with the design model ( Fig. 4A-C) . Despite twinning in the crystals, examining unbiased omit maps allowed modeling of unexplained density in the engineered binding site as FPP (Fig. 4B, Fig. S10 ) and confirmed the side chain conformations in the designed binding pocket (Fig. 4C, D) . Overall, in a 10 Å shell around FPP in the binding pocket, the Cα root mean squared deviation (rmsd) between the 5 model and the structure is 0.53 Å and the all heavy atom rmsd is 1.13 Å. While crystals formed only in the presence of FPP, only one of the two complexes in the asymmetric unit contained FPP in the binding site (Fig. S11) . This behavior allowed us to compare apo and holo states of the complex. The majority of the designed side chains are in identical conformations in the FPPbound holo and FPP-minus apo states (Fig. 4E) , suggesting favorable pre-organization of the 10 designed binding site. An exception is W114 on AR that is partly disordered in the apo state (Fig. S11) , providing a potential explanation for why a W114A mutation is not as detrimental for sensor activity (Fig. 2F) as expected based on the observed packing interactions between W114
and FPP in the holo state. A second slight deviation between the model and the crystal structure appeared to be caused by potential steric clashes of the engineered Y197 on MBP with the 15 modeled FPP conformer, which led to re-arrangements in the FPP structure and a rotamer change in another designed residue on MBP, F133 (Fig. 4D) . Interestingly, many of the original models from computational design favored a smaller alanine side chain at this position ( Fig. 2A) . These observations led to the prediction that a Y197A mutation might stabilize the ternary complex, and indeed design S3-3A containing the Y197A mutation showed an increased (>200 fold) 20 stabilization of the complex with FPP, with an apparent dissociation constant of the designed AR and MBP proteins comprising sensor S3-3A in the presence of 200 µM FPP of 870 ± 60 nM (Fig. 3B, C) . We also confirmed that design S3-3A (Table S1 ) is active in E. coli (Fig. S12) . To further improve the design based on the crystal structure of design S3-2D, we employed an additional round of flexible backbone design using the Rosetta "CoupledMoves" method (24) starting from the FPP-bound crystal structure. These simulations suggested 3 additional mutations leading to design S3-3B: R145K, K147L, D155L (Fig. 3A) . These mutations, when combined with the Y197A mutation (design S3-3C), enhanced the apparent binding affinity of 5 the designed AR and MBP proteins comprising sensor S3-3C in the presence of 200 µM FPP to 170 ± 20 nM (Fig. 3C, E) , but also strengthened the binding affinity of the protein-protein dimer in the absence of FPP to 6.2 ± 0.3 µM (Fig. S13) . Taken together, the crystal structure confirmed the engineered de novo binding site at atomic accuracy and provided key insights leading to further computational predictions that improved the apparent binding affinity of the sensor 10 proteins in the presence of FPP to the nanomolar range (sensor S3-3A).
A main advantage of our CID design strategy is the ability to link an engineered sensor, whose input is specific to a user-defined small molecule signal, to a modular output that can in principle be chosen from many available split reporters (Fig. 1A) . To test this concept, we linked the 15 engineered CID sensors S3-2D and S3-3A to two additional outputs, a dimerization-dependent fluorescent protein(31) and split luciferase(32) (Fig. 3G, H, Appendix 3) . We tested inputoutput responses with the two different reporters using an in vitro transcription-translation system (TxTl) (33) in which FPP can be added at defined concentrations to the assay extract, in contrast to the cell-based split mDHFR assay. The TxTl assay revealed a nanomolar FPP 20 sensitivity (K D app ) for our best sensor S3-3A (Fig. 3F ) that is essentially identical for both reporters (180 ± 50 and 330 ± 130 nM by luminescence and fluorescence detection, respectively, (Fig. 3E, Fig. S13 ), (ii) functional over a relevant dynamic range in cells that produce FPP from metabolic precursors (Fig. 2G) , and (iii) have modular compatibility with several reporter outputs (Fig. 2B, C, Fig. 3G, H Table S1 , Fig. S1 for all designs and Appendix 4 for complete sequences). Grey shading: preferred residues from flexible backbone reshaping (Fig. 1B) . Orange shading: individual 5 computational designs selected based on ligand burial (S3-1A), consensus (S3-1B), optimized ligand packing (S3-1C) and predicted ligand binding score (S3-1D). Blue shading: sensors stabilized by 2 additional mutations from single site saturation mutagenesis (note that designs S3-2B and S3-2C also contained 2 mutations from error-prone PCR that were not in the designed FPP binding site, see Table S1 ). Variants S3-3A-C contain mutations in S3-2D computationally designed to improve the stability of the ternary S3-2D In panels (C-E), residues are labeled black when designed and green/blue when present in the original scaffold complex.
